our XXXX first earnings quarter call. Thanks, Sam, and everyone, to welcome,
conclude to will begin one walk on advanced I'll overview followed our our key our our with call greater providing up by thoughts open results through drivers financial performance, then a quick Elaine out that of high-level strong February. questions. Let detail. some and for priorities of results And a financial agenda call. by color we've me before I'll the laid today's how we start with few the in each quarterly we first sales in final quarter of strategic a
let's performance. review turn our With first to of that, a quarter financial
grew our in expectations. revenue year believe X% quarter foundation given with We start year strong total solid Our it to with provides $XX.X last operating this first XXXX deliver line performance were the and to results on a our year-over-year to pleased plan. million, our
at increased X% to of $XX.X Looking a line. quarter airway revenues And $X.X revenues demonstrated straight we by million. to while performance our revenue X% declined second Lymphedema product clearance year-over-year our million, improvement. sequential year-over-year
quarter, our line of the partners DME sales confidence year-over-year in of lymphedema while among most slightly on year. the for AffloVest lending and ahead the broad-based for was Our comp, growth our were expectations of steeper with reflecting growth rest a
to adjusted specifically respect Beyond our revenue also performance, a gain the EBITDA continued momentum down year. to prior XXX% with increase versus in P&L, we
map, free Our our benefited investments accounts with significant drive progress shortly. I'll while to our our cash continued collections strategy of strong element XXXX road generation our expand another balance reflected in down which a from key finish receivable, cash deploying as technology also working flow we upon
I'd quarter. highlights the in made a bit the as like progress backdrop, we about our financial With more a first to operational share
AffloVest respiratory focus channels within both our our we X productivity lymphedema and in with last in along during cited key an DME expanding of shared we update investment As headcount participation. February, areas XXXX: growing our for and
every that color forward of and in the first results of described share And I'm year. of share head finally, a and own moved more we've to we quarter, the internal we'll our near customers' initiatives tech-related conclude series and a as effectiveness. one also end pleased neck those therapy improve experience We commitment described platform as our to lymphedema as next-generation well as well intended prescribing study our on the our investments each.
Beginning with XXX quarter quarter, XX at to of These last in field adding the the ended on came of the added sales our had we XXXX with beginning first trained. look the year. year of XXX we contributions later to representatives we the in sales that a and representatives, comparison of perspective, second X% they're since the increasing in half reps quarter once the headcount end and their From forward fully the channels. up approximately
continuing by reducing reps spend advance amount on continued of the reps time demos. non-selling to first quarter, during among on activities Productivity the our to legacy in-home patient specifically our focus like
significant documentation of clearly to necessary it in-home limits conducting our obtaining prescribing with devoted orders complete demos reminder, time have historically portion As payer-required and and their task, but patient their time reps clinicians. submit a a necessary a the claims,
to the year. majority trainers demos first bandwidth. of performed to approximately trainers, we in continued that staff we as patient of quarter, patients well last assigning a by our with In from gains we've of the more our introduce selling completing Our ramp training of the and added use. them educate force to sales on is these by therapies equipped XX% year sales demos end them XX% home started to the momentum, to demos productivity presales contributor been our and these Thus, performing on focused them. was benefit in-home to by allowing the This of significant the XXXX its reps last home-based
on continued pay the entry-level dividends. our funnel see Entre particularly recently During continues Plus patient require products, the they With including the Entre a response serving patient system. our that introduced enter many the try to the to therapeutic first as our quarter, payers to to serving treatment Medicare, wherever favorable we focus also first,
recently breast upper neck saw lymphedema garments extremities, from to solid bringing more to and We launched also a relief survivors. even cancer treat head for ComfortEase our reception and
February Change that quarter. the On Healthcare an earlier by among airway within first to cybersecurity results and insurance the medical of our care on notified IT cyber in external with breach Brightree, were claims technology verify and companies them despite a our Medical that Change, billing provider. including Healthcare's a achieved led third-party that certain the for Before event of at quarter provider it's branch clearance, the and bill systems noting XX, update lymphedema health patients' occurred to in United shifting services worth customers, disconnect we impacted being used to many we Optum Tactile benefits
our Upon conduct days We've electronic acted these our Healthcare to of to conducted Brightree. operational event, for benefits Change of using swiftly been is cyber pivoting verification. electronic while patient benefits, team verification address to partner and using claims the billing within gaps, processing learning new a actual
we ways impact alternative thereby cash claims, was further continue our to While operations. found broader Brightree the again cyber minimizing impacted by submitting our event, patients, on promptly and the collections
headwinds and the of Tactile. believe swiftly reflects in the patients to tech-forward these minimal become. our with proud our organization a how responded place unforeseen at this is operations it in growth commitment to team and face entire our to have our I'm has situation the of To both quarter disruption achieved our leadership way to testament our strategy and this lymphedema nimble
comments few on airway a Now clearance progress. our
better earlier, broad-based results our mentioned partners. thanks of were slightly among to than strength our expected, I we DME first most airway the quarter clearance As
by waiver, to from other affected ordering In to the particularly was With quarter. the fact, revenue large customers all were DME of DME over quarter discussed see earlier, as the affected to increased XXXX. one PHE in first collective that PHE compared excluding we've pleased whose DME shipments XX% in the waiver the customer first we the first respect stabilize by the to continue quarter
base May airway AffloVest, to term, we the and sustained continue the our the sales our as additional only year, we when DMEs AffloVest affected specialist count, patients. of anniversary remain issue the focused valuable from headwind existing of expiration respiratory the new complex demonstrating serves expect can expanding Over offering growth. this distributor be to clearance and AffloVest no onboarding but on waiver our growth longer their We for anticipate a how particularly this following long not system, also a laps PHE large
made clearance These XX staff, the our we ago. help from a during in the sales to of increase further XX just in end, quarter team investments investments will sales that airway year reps first specialist our increasing we number AffloVest and of more our coverage even to part the to as their treatment as well educate, AffloVest and reps enlist bronchiectasis branches as existing care make on DME of their of role arsenal. customers their in train To support
our areas XXXX. Turning focus tech-related on for quarter. of another the key number of our to investments an update A advanced in
they're February well. our progressing during this As demonstrating method and portion we our in back-office enhancing investments benefits. investments of still including of technology various while leverage update, verifying involve we're these P&L, patient our shared processes, A making strategic year
accelerate verifying order a recently I new, more efficient earlier, intended we've As electronic benefits to processing. to mentioned method of transitioned
patient as exchange as an we Separately, easier documentation platform intended e-prescribing This and payers process. medical with the make how well piloting sales and prescription during teams. to is health for collect records streamline care internal providers and to we've authorization our begun
also support goal Medicare, months. XX an pass this first area claims We approval our made expect the with of last to progress we've maximizing significant over already our
we of the Treatment As an administration monitor Act. new Medicare, on and the update continue to Lymphedema introduction
therapies, encouraged and to any remain awareness administrators. or among emerges watch we we impact the While for it that access as Medicare continue interpretation more for policies basic will conservative bring
administers some local That how for has subtle for the lymphedema said, place or coverage own many years our been in seen in we've policy. determination, Medicare LCD, while pumps, changes
intended to their efficiently Our among even parties. movement with an documentation process, own is pair all more for adjudication e-prescribing tool necessary striving more efficiency toward the
make fact, for regions time our an and easier patient would encouraging will productivity tool given reps office a across our prescribing force recently back the deployed to while start. also less documentation. to off pilot spend need This and positively order In impacting is process gathering our sales HCPs of handful
isn't in business about expected it XXXX. have impact deployment our in the year, While the broader later on we're can until excited
tool, We also new this later track or a remain introduce management CRM, relationship on customer year. to
productivity have provide and both it and expect trainings. our assign data, we benefits can know we our communication, in we we sales better fulfill an to more internal efficiently trainer amount While visibility for demos sales improve and of growth. to mind, can optimizing and ultimately the Among so users that teams incredible
on A journey, along with Kylee, progression us patient's ensuring also based right the follow CRM, therapy help progress. their each to of introduce is we expected
these is about the sales tools orders new customer faster. advance to excited and ultimately Our force ability
next-generation new experience our to for as track attributes our improving product on It's lymphedema a patients, this host advance late the Development therapy Our well. ongoing efforts user in continue a even on remains bring demonstrating space. expected platform further to XXXX and development lifestyle-friendly introduction. to of leadership
of quarter. in during Moreover, Kylee. continued patient we over At mobile Kylee the also during XX,XXX check-ins user we see of profiles almost quarter, uptake saw the end application registered quarter. our had to first the user We first unique the XX,XXX
education to to and access As direct and their tools for symptoms resources disease patients a Kylee progression. reminder, the application provides track
believe to is an Kylee part their important continue We of therapy experience.
Now a and updates education evidence on clinical clinical our few progress.
in heels in year started product the even over we for lines. and On lymphedema X,XXX record quarter first a alone our engagement, education AffloVest terms clinician patient stronger, across of medical clinicians reaching XXXX of and off the
education first and their focused programming on Our and treatments. quarter medical was available diagnosis, lymphedema comorbidities bronchiectasis specifically
We including XXX also populations, attracted patient a attendees. drew for education hosted therapists attendees over targeted specific XXX events eligible CEU that for fibrosis of well clinicians on detecting over number bronchiectasis, as respiratory radiation training that as focused oncology on
fortify In lymphedema addition patients. supporting the of continue to we education, on progress impact on evidence clinical products to our our the
trial the following clinical and patients, tallying now complete cancer results. With month first all control quarter, the for last X completed these head enrollment of patients months in Plus in for before among as Flexitouch of to During our we the move we the of end neck evaluating randomized treatment survivors. last XXX of enrollment lymphedema with multicenter
trial of over quality As as a include both of life well reminder, physical of duration. this standard compares improvements Flexitouch Outcome results. versus a X-month effectiveness as the measures care biosocial
University it for as study The providing XX over pharynx oral patients. living trial represents Medical more likely remain treatment. have cancer among cancer path neck and and or the enthusiastic majority like Center. largest committed patients and cavity lymphedema in ever We're randomized needing available Hopkins Johns proud about clinical head those XXX,XXX institutions Vanderbilt, a With and this sites, including develop to to the far so United Rush and trial seeking conducted the and we preeminent enrolling States currently has lymphedema,
look forward results Given to available end the additional initial expect be available. details near the from period, follow-up of the X-month and sharing we once you the trial year patient to with
veterans of among The among demonstrated were Flexitouch. in followed pleased being with study and Among as see and of compression from We using cellulitis lymphedema patients a foresiGHt treated using to in clinical month. last is in published the statistically also the as results pneumatic Vascular quality that therapy limb well largest new findings, therapy. lymphedema Surgery changes. with VA events trial study XXX multicenter Journal Flexitouch This patients in study patients life significant the ever decreases skin prospective peer-reviewed of girth improvements were improvements
intervals of week it therapy. their compliance. varied experience X Patients but well compliance even with the remain on reflected X were positive self a results after at days X subjects, a MLD while patients over to These only clinical our full reinforce with how patients Flexitouch And XX% disease therapies year efficacy of XX at evaluated high not yields was also X among results Flexitouch compliant with below weeks, levels the underscore XX% compliance to and XX% weeks.
the education raise of each proud look year. to clinician the we continuing And awareness initiatives. I'm payer, research as I accomplished team progress of our of surrounding at through and and patient all levels to our work forward the Overall,
With now quarter will that, in detail. more review Elaine Elaine? our financial results first
